Background: Percutaneous neurostimulation of the peripheral nervous system involves the insertion of a wire "lead" through an introducing needle to target a nerve/plexus or a motor point within a muscle. Electrical current may then be passed from an external generator through the skin via the lead for various therapeutic goals, including providing analgesia. With extended use of percutaneous leads sometimes greater than a month, infection is a concern. It was hypothesized that the infection rate of leads with a coiled design is lower than for leads with a noncoiled cylindrical design. Methods: The literature was retrospectively reviewed for clinical studies of percutaneous neurostimulation of the peripheral nervous system of greater than 2 days that included explicit information on adverse events. The primary endpoint was the number of infections per 1,000 indwelling days. Results: Forty-three studies were identified that met inclusion criteria involving coiled (n = 21) and noncoiled (n = 25) leads (3 studies involved both). 
INTRODUCTION
Percutaneous neurostimulation within the peripheral nervous system involves the insertion of a wire "lead" through an introducing needle to target a nerve/plexus or a motor point within a muscle. [1] [2] [3] Electrical current may then be passed from an external generator through the skin via the lead for various therapeutic goals, including providing analgesia when treating chronic pain states. 4, 5 The original percutaneous leads had a noncoiled cylindrical shape-essentially simply a straight wire-and the majority of leads retain that structure ( Figure 1 ). However, an alternative lead design takes the form of an open-coiled helix (see Figure 1 ). 5, 6 Both designs have been used clinically for extended periods of time-over 12 months in some cases. [7] [8] [9] [10] Infection is a concern because the leads create a potential conduit for contamination as they traverse the skin, and other percutaneous devices (such as intravascular catheters) have historically had a relatively high risk of infection when left indwelling for extended periods of time. 11, 12 There is a theoretical reason to believe that infection risk might be associated with lead design. Transcutaneous contamination may be a consequence of small movements of the externalized leads relative to the exit site that cause a "pistoning" effect, transferring infectious agents from the externalized portion of the lead/ catheter to the subcutaneous tissues. Pistoning might also increase susceptibility to infection by disrupting the cell layer that forms around the lead (ie, encapsulation), which serves as an infection barrier. 13, 14 When a noncoiled, cylindrical lead traverses the skin, movement of the extremities can cause the wire to piston at the exit site. In contrast, an open-coil design allows the lead to stretch and compress to theoretically minimize the piston effect, while also allowing rapid tissue fibrosis into the helix, possibly hastening/improving a bacteriostatic seal ( Figure 2 ). 7, 13 However, the relative infection risks among these 2 designs remain unexamined for leads designed for percutaneous stimulation of the peripheral nervous system. We therefore conducted this retrospective investigation, hypothesizing that the infection rate of leads with open-coil design is lower than for leads with a noncoiled cylindrical design. The primary endpoint was the number of investigator-reported infections per 1,000 indwelling days, as per recommendations from the Centers for Disease Control and Prevention (CDC; Atlanta, Georgia, U.S.A.) for reporting catheter infection rates.
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METHODS
Literature Review
A literature review was conducted using PubMed to identify published articles involving percutaneous electrical stimulation of the peripheral nervous system with a mean indwelling time of more than 2 days. Studies were excluded if adverse events were not explicitly reported, if data were available only for nonhuman subjects, or if there were fewer than 8 subjects evaluated (eg, case reports and small series). Of interest were studies reporting data for stimulation targeting peripheral nerves and motor points within muscles (eg, sacral nerves, occipital nerves, upper and lower extremity nerves, etc.) and not studies reporting data for cardiac stimulation, cochlear stimulation, deep brain Figure 1 . Examples of (A) a coiled lead and (B) a noncoiled electrical lead used for percutaneous neurostimulation of the peripheral nervous system. stimulation, transcutaneous electrical stimulation, or spinal cord stimulation. Studies that only reported leads from a permanent (fully implanted) system were excluded from the analysis. If a study reported leads from both the trial (percutaneous) phase and the permanent (fully implanted) phase, only the leads from the former were included in the analysis. Duplicate data among studies were excluded. The following search terms were inputted for the initial PubMed search: "(((((neuromodulation) OR neurostimulation) OR nerve stimulation) OR electric stimulation) AND peripheral) AND percutaneous." The title, abstract, and manuscript were reviewed for all articles to determine if the reference was potentially appropriate for the current investigation. Among these, the articles listed in each reference section were also reviewed in a similar manner. This was performed iteratively until no additional original articles were found. Data were collected by 2 of the authors independently and subsequently cross-checked for accuracy. Conflicting data were reanalyzed by both authors and agreed upon by consensus, with a third author available to arbitrate any unresolved disagreements. No major disagreements occurred.
Infections were defined as purulent discharge, erythema, or cellulitis at the lead exit site treated with antibiotics. The number of infections in each study was recorded, with additional note taken of severe infections defined as requiring any intervention in addition to antibiotic administration (eg, abscesses, meningitis, surgical drainage, debridement). The time from insertion until infection was recorded, when available. The numbers of patients and leads used in each study were also recorded, along with the total indwelling duration. Duplicate data among publications were excluded.
When calculating the number of infections per 1,000 indwelling days, a range existed for each group's infection rate because some studies reported a range of indwelling times without reporting the mean indwelling time. Therefore, the highest possible infection rate for open-coil leads was compared to the lowest possible rate for noncoiled leads, ensuring conservative estimates were used to test for significant differences.
Data Analysis
Leads were grouped according to design (coiled vs. noncoiled). The primary endpoint was designated the rate of infection per 1,000 indwelling days, as per recommendations from the CDC for reporting catheter infection rates. 15 Secondary endpoints included analyses of the rate of infection in the first 30 and 60 days, necessarily restricted to the subgroup of studies, which report sufficient information to determine these rates. Potential confounding covariates included publication year, study design (eg, randomized, controlled trial vs. retrospective chart review), country of origin (within vs. outside of the United States), sex, aseptic technique (not described and none vs. sterile technique described), and pre-insertion antibiotic administration.
The primary analysis approach was a generalized linear model with the outcome modeled as Poisson with quasi-likelihood to account for study heterogeneity or 
RESULTS
The initial search yielded a total of 235 references. Among these, 24 articles were deemed potentially appropriate for the study, 8 of which met inclusion criteria for the study. Articles listed in each article's reference list were also reviewed, which led to a final count of 43 articles meeting inclusion criteria involving coiled (n = 21; Table 1 ) and noncoiled (n = 25; Table 2 ) leads (with 3 articles involving both designs). The percentage of male subjects met our criteria to be deemed a potential confounder ( Table 3 ). The percentage of males was significantly associated with infection rate (for each percentage increase in males, the risk of infection dropped by a factor of 0.95; 95% CI 0.93 to 0.98; chi-squared test P = 0.003) and coil type (for each percentage increase in males, the odds that the study was of coiled leads increased by a factor of 1.05; 95% CI 1.01 to 1.09; P = 0.002). There was a significant association between coil type and overall infection rate with and without controlling for the percentage of males. No other covariate was determined to be a potential confounder.
Primary Endpoint
The risk of infection with noncoiled leads was estimated to be 25 times greater than with coiled leads (95% CI 2 to 407; chi-squared test P = 0.006) controlling for the percentage of males. The infection rates were estimated to be 0.03 (95% CI 0.01 to 0.13) infections per 1,000 indwelling days for coiled leads, and 0.83 (95% CI 0.16 to 4.33) infections per 1,000 indwelling days for noncoiled leads. The effect of the percentage of males was not significant in this model. Without adjusting for the percentage of males, the risk of infection with noncoiled leads was estimated to be 21 times greater than with coiled leads (95% CI 8 to 54; chi-squared test P < 0.001).
Secondary Endpoints
The risk of infection over the first 30 days was 4 and 5 times higher for noncoiled compared with coiled leads after 30 days (chi-squared test P = 0.20) and 60 days (chi-squared test P = 0.14), respectively ( Figure 3) . The estimated 30-day infection rates were 0.1% for coiled and 0.5% for noncoiled leads. Similarly, the estimated 60-day infection rates were 0.1% for coiled and 0.7% for noncoiled ( Figure 3 
DISCUSSION
The principal finding of this retrospective study involving electrical leads used for percutaneous neurostimulation of the peripheral nervous system was that the infection rate of noncoiled cylindrical leads is far higher -25 times higher-than the rate for coiled leads. To put this difference in perspective, 1 infection occurred approximately every 1,200 indwelling days for noncoiled leads compared with 1 infection for every 30,000 indwelling days for coiled leads. With many therapeutic goals requiring multiple weeks of stimulation, these findings could have significant implications in the choice of a lead design for percutaneous neurostimulation. The reason(s) for the difference in infection rate between lead designs remain unknown, but there are theoretical explanations that deserve future study. The open-coil design might permit fibrosis at the insertion site, leading to both a superior bacteriostatic seal at the skin and a solid anchor preventing lead movement (see Figure 2) . 13 The coiled leads can also flex, bend, or "uncoil" inside muscle and soft tissue, which minimizes translation of the lead relative to the skin. Decreasing lead movement would theoretically decrease any "pistoning" effect that could draw pathogens subcutaneously. 7, 13 In addition, most of the coiled leads had a small diameter (0.2 mm) of the lead wire and even of the entire helix itself (< 0.6 mm) relative to most of the cylindrical noncoiled leads (0.6 to 1.3 mm) and would therefore create a relatively smaller exit site. Insertion needles were presumably smaller for the smaller diameter leads as well-and did not require a surgical incision for placement-possibly further decreasing the infection risk. Unfortunately, this information was not available from all sources, and therefore, any conclusions can only be inferred regarding this attribute that deserves further study.
To help put the observed infection rates found in the current study in clinical perspective, it is useful to compare to other types of techniques with similar therapeutic goals. For example, percutaneous neurostimulation has been reported to treat both phantom limb pain 5, 18 and acute postoperative pain, 19-21 as has ambulatory perineural local anesthetic infusion. 22 The percutaneous perineural catheters used for continuous peripheral nerve blocks have an approximate diameter Figure 3 . Infection rates for coiled and noncoiled leads used for percutaneous neurostimulation of the peripheral nervous system reported as (A) infections per 1,000 indwelling days (individual study infection rates represented with circles along the axis of the log scale identify infection rates of < 0.01 per 1,000 indwelling days) and (B) infection rates during the first 30 and 60 indwelling days.
of 0.8 to 1.0 mm and a noncoiled cylindrical profile. Although they rarely remain in situ for longer than 6 days, the published infection risk is 1.5% (175 infections in 12,078 catheters), 23 compared with 30-day infection rates of 0.1% and 0.5% for coiled and noncoiled percutaneous leads of the current study, respectively. Other temporary percutaneous therapies left indwelling more than 2 days such as spinal cord stimulators, continuous epidural blocks, and intrathecal treatments have also been reported to carry a higher risk of infection (mean of 1.0% to 1.6%) during indwelling times of up to 30 days.
LIMITATIONS
Infection rates could be overestimated in this analysis if prior studies did not explicitly mention the absence of infections and were thus excluded from our analysis. Similarly, infection rates could also be underrepresented for the same reason, if infections occurred in prior investigations but were not reported. It is reassuring that a previous study from 2002 reviewing the infection rates of coiled leads reported a 0.1% infection rate during the first 60 indwelling days-similar to the present finding of 0.1% within 30 and 60 days. 12 This previous uncontrolled investigation reported on 62 subjects implanted with 858 leads with solely the coil design, unlike the current investigation with 513 subjects and 4,140 leads from 24 trials with a comparison group of noncoiled leads. In the current investigation, not all identified publications were included in every infection rate calculation because of unavailable data (eg, if the exact timing of infections were not reported). For example, 5 of 21 open-coil lead studies were not included in the calculation of the 30-day infection rate because the timing of infections was not adequately reported (see Table 1 ). The 5 excluded studies had an overall infection rate of 2.3%, compared to a rate of 1.0% in the other 16 included studies. However, the excluded studies had an average indwelling time of 448 days per lead, compared to 241 days per lead in the included studies. Calculation of the rate of infections per 1,000 indwelling days allowed many of the studies that did not report exact timing of infections to be included, and this again demonstrated that the rate of infection with open-coil leads (0.03 infections per 1,000 indwelling days) was an order of magnitude lower than the comparison group composed of noncoiled leads.
In addition, factors other than the design of the electrical leads could have influenced the calculated infection rates, but all variables could not be controlled in the current investigation due to lack of published information. For example, only 8 studies explicitly mentioned the utilization of prophylactic antibiotics; however, the use of prophylactic antibiotics in the other studies was unclear. Sterile technique may also play a role in infection rate; however, the available information was inadequate to draw any conclusions. Male gender was deemed a potential confounding factor, but further analysis found that the type of lead (coiled or noncoiled) and the risk of infection were still significantly associated even when controlling for the percentage of males. None of the other variables included in this analysis were determined to be confounding factors.
In conclusion, the infection rate during percutaneous neurostimulation of the peripheral nervous system differs by lead design: 0.03 vs. 0.83 per 1,000 indwelling days for coiled and noncoiled leads, respectively. With many therapeutic goals such as functional improvements and the relief of pain requiring multiple weeks of stimulation, these findings could have significant implications in the choice of a lead design and the potential for extending the use of percutaneous peripheral neurostimulation.
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